These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33828565)

  • 1. Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
    Shao J; Hou L; Liu J; Liu Y; Ning J; Zhao Q; Zhang Y
    Front Immunol; 2021; 12():661357. PubMed ID: 33828565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma.
    Mei Z; Zhang K; Lam AK; Huang J; Qiu F; Qiao B; Zhang Y
    Cancer Med; 2020 Jan; 9(2):640-652. PubMed ID: 31800160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.
    Huang Q; Xia J; Wang L; Wang X; Ma X; Deng Q; Lu Y; Kumar M; Zhou Z; Li L; Zeng Z; Young KH; Yi Q; Zhang M; Li Y
    J Hematol Oncol; 2018 Apr; 11(1):58. PubMed ID: 29685162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression.
    Khoshkhabar R; Yazdani M; Hoda Alavizadeh S; Saberi Z; Arabi L; Reza Jaafari M
    Int Immunopharmacol; 2024 Aug; 137():112437. PubMed ID: 38870880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
    Chen B; Alvarado DM; Iticovici M; Kau NS; Park H; Parikh PJ; Thotala D; Ciorba MA
    Cancer Immunol Res; 2020 Apr; 8(4):451-464. PubMed ID: 32127391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
    Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
    J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
    Jochems C; Fantini M; Fernando RI; Kwilas AR; Donahue RN; Lepone LM; Grenga I; Kim YS; Brechbiel MW; Gulley JL; Madan RA; Heery CR; Hodge JW; Newton R; Schlom J; Tsang KY
    Oncotarget; 2016 Jun; 7(25):37762-37772. PubMed ID: 27192116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
    Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
    Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.
    Patra T; Cunningham DM; Meyer K; Toth K; Ray RB; Heczey A; Ray R
    Mol Ther; 2023 Mar; 31(3):715-728. PubMed ID: 36609146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.
    Zhang PF; Huang Y; Liang X; Li D; Jiang L; Yang X; Zhu M; Gou HF; Gong YL; Wei YQ; Li Q; Wang W
    FASEB J; 2020 Aug; 34(8):11185-11199. PubMed ID: 32645243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
    Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
    Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
    Röhrig UF; Reynaud A; Majjigapu SR; Vogel P; Pojer F; Zoete V
    J Med Chem; 2019 Oct; 62(19):8784-8795. PubMed ID: 31525930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
    Shi JG; Bowman KJ; Chen X; Maleski J; Leopold L; Yeleswaram S
    J Clin Pharmacol; 2017 Jun; 57(6):720-729. PubMed ID: 27990653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
    Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Nonviral
    Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
    Front Immunol; 2021; 12():802705. PubMed ID: 35082789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Li A; Barsoumian HB; Schoenhals JE; Caetano MS; Wang X; Menon H; Valdecanas DR; Niknam S; Younes AI; Cortez MA; Welsh JW
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):903-912. PubMed ID: 30905636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.